Thomas Zikos, MD
Internal Medicine · Los Angeles
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 14 years
- University of Pittsburgh School of Medicine, 2012
Offices
1 location · Southern California Permanente Medical Group · 11,250 clinicians in this group
Hospitals listed: Kaiser Foundation Hospital - West La. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Zikos’s office at (800) 954-8000 to ask if they take your plan before you enroll.
California Medical Board record
Licence A126604 · Current
Licensed to practise in California · since 2013 · expires 2028-09-30 · University of Pittsburgh School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Gastroenterology
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Kaiser Foundation Hospital - West LaLos Angeles, CAAcute Care Hospital · Voluntary non-profit - Private · No emergency department · Birthing-friendlyPart of Kaiser Permanente, which runs 41 hospitals in 3 statesPatients rate it 3 of 5 · 73% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.384, Oct 2024 – Sep 2025
See every measure and the patient survey for Kaiser Foundation Hospital - West La
Behind the star rating — Deaths: 0 better, 3 the same, 0 worse of 3 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 2 the same, 1 worse of 3 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.384 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.31 (0.23 to 2.38) · 180 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.91 (0.47 to 1.34) | No different | Jul 2022 – Jun 2024 |
| Death rate for heart failure patientsComplications and deaths | 9.2 · 28 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 39 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 15.1 · 209 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.3 · 2,005 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 945 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.05 to 0.48) · 992 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.73 (1.19 to 6.28) · 133 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.66 (0 to 3.39) · 26 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.9 (1.2 to 4.61) · 132 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.5 (0 to 18.2) · 30 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.12 (0.82 to 9.41) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.09 (0.57 to 3.62) · 36 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 1.3) · 804 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.464 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.583 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.316 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.508 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 95 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.6 · 399 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 84.9 · 28 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 45 · 35 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 382 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.3 · 188 cases | None | Jul 2023 – Jun 2025 |
What patients said (358 patients answered, 17% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 73% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 51% |
| "YES", patients would definitely recommend the hospital | 73% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$2,434
Medicare paid this office $2,434 for 19 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Procedures Medicare counted
| Colonoscopy | 1-10 | None |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 12 | More than 44% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | – | 37 | 15 | – | – | – |
| Biopsy of large bowel using a flexible endoscope | 11 | 23 | – | – | – | – |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | – | 23 | – | – | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
19 Original Medicare patients in 2024. Average age 66 · Health risk score 1.64. At or below the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 63%.
The office billed $26,010, Medicare allowed $3,559 and paid $2,434; for 26 services of 12 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 19 | 26 | 66 | 1.64 | $26,010 | $2,434 |
| 2023 | 19 | 34 | 62 | 1.60 | $25,380 | $5,262 |
| 2022 | 20 | 30 | 65 | 2.09 | $26,032 | $6,537 |
| 2021 | 175 | 331 | 69 | 2.10 | $311,974 | $34,424 |
| 2020 | 226 | 532 | 69 | 1.66 | $585,397 | $46,409 |
| 2019 | 124 | 229 | 72 | 1.30 | $220,053 | $23,587 |
| 2016 | 41 | 44 | 61 | 5.47 | $22,193 | $5,672 |
| 2015 | 40 | 44 | 66 | 2.99 | $20,566 | $5,451 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2021: 7 services
| Long return visit (40+ min) | 42 | $6,226 | $127 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $4,290 | $187 |
| Return visit (30+ min) | 31 | $2,748 | $81 |
| New patient visit (60+ min) | 15 | $2,443 | $163 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 14 | $2,005 | $134 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,378 | $125 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 12 | $125 | $10 |
2020: 15 services
| Long return visit (40+ min) | 70 | $8,810 | $104 |
| New patient visit (60+ min) | 55 | $8,729 | $159 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 23 | $5,483 | $238 |
| Return visit (30+ min) | 49 | $4,599 | $73 |
| Biopsy of large bowel using a flexible endoscope | 23 | $1,884 | $82 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 25 | $1,612 | $62 |
| Telephone medical discussion with physician, 21-30 minutes | 11 | $1,482 | $78 |
| Study of rectum sensitivity and function | 17 | $1,266 | $74 |
| Study of esophagus to assess movement | 20 | $1,039 | $52 |
| Monitoring and recording of esophageal function through nasal tube with electrode | 20 | $857 | $43 |
| Telehealth originating site facility fee | 29 | $678 | $21 |
| Test for tone and sensation of rectum and anus | 17 | $638 | $38 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $563 | $51 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 18 | $169 | $9 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 12 | $49 | $4 |
2019: 8 services
| New patient visit (60+ min) | 38 | $6,245 | $164 |
| Long return visit (40+ min) | 29 | $3,916 | $119 |
| New patient visit (45+ min) | 13 | $1,845 | $142 |
| Return visit (30+ min) | 12 | $1,403 | $88 |
| Biopsy of large bowel using a flexible endoscope | 11 | $852 | $77 |
| Study of esophagus to assess movement | 13 | $797 | $61 |
| Monitoring and recording of esophageal function through nasal tube with electrode | 11 | $512 | $47 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 16 | $149 | $9 |
2016: 1 service
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $4,366 | $175 |
2015: 2 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $3,628 | $181 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 11 | $419 | $35 |
Drugs they prescribed that Part D paid
$140,762
Pharmacies billed $140,762 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
394 generic and 85 brand-name prescriptions · $140,762 in drug cost · 55 antibiotic prescriptions to 26 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xifaxan | 14 | $32,557 | $2,325 |
| Linzess | 15 | $26,917 | $1,794 |
| Motegrity | 16 | $19,632 | $1,227 |
| Lubiprostone | 27 | $4,043 | $150 |
| Omeprazole | 145 | $1,652 | $11 |
See all 12 drugs
| Xifaxan | 14 | $32,557 | $2,325 |
| Linzess | 15 | $26,917 | $1,794 |
| Motegrity | 16 | $19,632 | $1,227 |
| Lubiprostone | 27 | $4,043 | $150 |
| Omeprazole | 145 | $1,652 | $11 |
| Tetracycline | 14 | $536 | $38 |
| Gavilyte-C | 23 | $532 | $23 |
| Lactulose | 11 | $421 | $38 |
| Dicyclomine | 12 | $402 | $33 |
| Pantoprazole | 22 | $280 | $13 |
| Metronidazole | 19 | $172 | $9 |
| Ondansetron Odt | 12 | $127 | $11 |
Year by year
| 2024 | 479 | 187 | None | 18% | $140,762 |
| 2023 | 414 | 167 | None | 20% | $141,013 |
| 2022 | 433 | 145 | 3% (12) | 29% | $100,093 |
| 2021 | 446 | 145 | None | 22% | $80,906 |
| 2020 | 362 | 132 | 0% (0) | 26% | $55,040 |
| 2019 | 102 | 63 | 0% (0) | 26% | $18,837 |
| 2016 | 11 | None | 0% (0) | None | $3,555 |
| 2015 | 28 | None | None | None | $655 |
| 2014 | 16 | None | None | None | $552 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 10 drugs
| Motegrity | 17 | $25,390 | $1,494 |
| Linzess | 15 | $20,973 | $1,398 |
| Creon | 15 | $16,814 | $1,121 |
| Omeprazole | 121 | $1,344 | $11 |
| Dicyclomine | 17 | $733 | $43 |
| Tetracycline | 12 | $434 | $36 |
| Gavilyte-C | 17 | $365 | $21 |
| Pantoprazole | 19 | $320 | $17 |
| Diphenoxylate-Atropine | 14 | $291 | $21 |
| Metronidazole | 13 | $151 | $12 |
2022: 13 drugs
| Linzess | 18 | $20,603 | $1,145 |
| Creon | 14 | $13,616 | $973 |
| Lubiprostone | 38 | $11,857 | $312 |
| Motegrity | 13 | $7,442 | $572 |
| Trulance | 14 | $5,229 | $374 |
| Rabeprazole | 13 | $786 | $60 |
| Omeprazole | 75 | $750 | $10 |
| Dicyclomine | 18 | $718 | $40 |
| Esomeprazole Magnesium | 17 | $651 | $38 |
| Pantoprazole | 22 | $320 | $15 |
| Gavilyte-C | 16 | $316 | $20 |
| Famotidine | 17 | $194 | $11 |
| Gabapentin | 13 | $143 | $11 |
2021: 9 drugs
| Linzess | 35 | $21,032 | $601 |
| Creon | 11 | $11,413 | $1,038 |
| Omeprazole | 93 | $1,509 | $16 |
| Pantoprazole | 67 | $1,247 | $19 |
| Pyridostigmine | 19 | $992 | $52 |
| Esomeprazole Magnesium | 13 | $684 | $53 |
| Dicyclomine | 19 | $610 | $32 |
| Famotidine | 21 | $518 | $25 |
| Gabapentin | 13 | $168 | $13 |
2020: 10 drugs
| Creon | 11 | $12,733 | $1,158 |
| Linzess | 24 | $12,108 | $504 |
| Omeprazole | 59 | $1,177 | $20 |
| Pyridostigmine | 13 | $1,027 | $79 |
| Pantoprazole | 29 | $589 | $20 |
| Dicyclomine | 17 | $401 | $24 |
| Gavilyte-G | 29 | $391 | $13 |
| Promethazine | 12 | $351 | $29 |
| Gabapentin | 11 | $164 | $15 |
| Gavilyte-C | 12 | $163 | $14 |
2019: 2 drugs
| Gavilyte-G | 29 | $410 | $14 |
| Omeprazole | 11 | $251 | $23 |
Money from drug and device companies
$60 in 2024
| 2024 | 1 | 2 | None | $60 |
| 2023 | 1 | 1 | None | $21 |
| 2022 | 1 | 2 | None | $63 |
| 2021 | 1 | 1 | None | $45 |
| 2019 | 1 | 1 | None | $102 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | Apollo Esg Nxt System | $60 | 2 payments
|
See all 2 published payments
| Boston Scientific | Meals · 2024-11-01 | Apollo Esg Nxt System | $34 |
| Boston Scientific | Meals · 2024-09-17 | Orcapod | $26 |
See earlier years (2023, 2022, 2021, 2019)
2023: $21
| Boston Scientific | None | $21 | 1 payment
|
2022: $63
| Boston Scientific | General - Polypectomy | $63 | 2 payments
|
2021: $45
| Boston Scientific | General - Biliary Devices | $45 | 1 payment
|
2019: $102
| AbbVie | None | $102 | 1 payment
|
Professional record
- NPI
- 1801162904
- Licence
- CA A126604California A126604: Current · expires 2028-09-30
- Trained
- University of Pittsburgh School of Medicine, 2012 · 14 years ago
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Grant S101, Stanford, CA, 94305
- NPI first listed
- 2012-03-22
- NPI last updated
- 2021-11-29
- NPI record certified
- 2021-11-24
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.